TENT COOPERATION TRE

From	tha	INT	FRN	ΔΤ	ION	ΔΙ	RH	REAL	ı
CIOID	11111	113 1	EDIN	AI	IL JIV	AL	DU	RFAI	

	TION the INTERNATIONAL BOILEAU
PCT	То:
NOTIFICATION OF ELECTION (PCT Rule 61.2)	Assistant Commissioner for Patents United States Patent and Trademark Office Box PCT Washington, D.C.20231 ETATS-UNIS D'AMERIQUE
Date of mailing (day/month/year) 13 June 2000 (13.06.00)	in its capacity as elected Office
International application No.	Applicant's or agent's file reference
PCT/US99/17167	PF-0568 PCT
International filing date (day/month/year)	Priority date (day/month/year)
30 July 1999 (30.07.99)	31 July 1998 (31.07.98)
Applicant Class and I	
BANDMAN, Olga et al	
1. The designated Office is hereby notified of its election many in the demand filed with the International Prelimina 02 February 2 in a notice effecting later election filed with the International Prelimina 02 February 2 The election was was made before the expiration of 19 months from the priority Rule 32.2(b).	ry Examining Authority on: 2000 (02.02.00) rnational Bureau on:
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20 Switzedand	Authorized officer Kiwa Mpay

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35



From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: LUCY J. BILLINGS
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE
PALA ALTO, CA 94304

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing (day/month/year)

22 JAN 2001

Applicant's or agent's file reference

PF-0568 PCT

IMPORTANT NOTIFICATION

International application No.

International filing date (day/month/year)

Priority Date (day/month/year)

PCT/US99/17167

30 JULY 1999

31 JULY 1998

Applicant

INCYTE PHARMACEUTICALS, INC.

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KAREN COCHRANE CARL DELLA MAE COLLINS
PARALEGAL SPECIALIST

Telephone No. (703) 308-0 PECHNOLOGY CENTER 1600

Form PCT/IPEA/416 (July 1992)*



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

pplicant's or agent's file reference PF-0568 PCT	FOR FURTHER ACTION	Preliminary	ation of Transmittal of International Examination Report (Form PCT/IPEA/416)
nternational application No.	International filing date (day/n	nonth/year)	Priority date (day/month/year)
PCT/US99/17167	30 JULY 1999	Ţ	31 JULY 1998
nternational Patent Classification (IPC) Please See Supplemental Sheet.	or national classification and IF	PC	
applicant INCYTE PHARMACEUTICALS, IN	C.		
Examining Authority and 1 2. This REPORT consists of a This report is also account.	a total of sheets. mpanied by ANNEXES, i.e., she	eets of the desc	ription, claims and/or drawings which have grectifications made before this Authority.
(see Rule 70.16 and Se	ection 607 of the Administrative	Instructions u	inder the PCT).
These annexes consist of a			
3. This report contains indicati	ons relating to the following:	items:	
I X Basis of the rep	port		
II Priority			
		ovelty inven	tive step or industrial applicability
٠		,,	
IV Lack of unity of	of invention		1
V X Reasoned statem citations and exp	nent under Article 35(2) with re planations supporting such state	egard to noveltement	y, inventive step or industrial applicability;
VI Certain documen	its cited		
VII Certain defects i	n the international application		
	ions on the international applica	ation	
			·
Date of submission of the demand	Da	ate of completion	on of this report
Date of anomination of the domain		or promise	A .
02 FEBRUARY 2000		06 DECEMB	
N	FA/US Au	thorized office	THAT OF CENTER AS
Name and mailing address of the IP	ademarks	**	
Box PCT Washington, D.C. 20231			DELLA MAE COLLING
Facsimile No. (703) 305-3230	Te	elephone No.	(703) 308-0196



International application No.

PCT/US99/17167

I.	Ba	sis of t	he report				
	W.L	magned to	o the elements of the inte	emational annlica	tion•*		
1.			ernational application				
	X			us originari,			
	X		scription: 1-58				, as originally filed
						<u> </u>	, filed with the demand
		pages _			filed wit	h the letter of	
		pages _	NONE		, med with		
		the cla	ims.				
	X	pages	1-20				, as originally filed
		pages			, as amend	led (together with an	y statement) under Article 19
		pages	NONE				, filed with the demand
		pages		, filed	with the letter	of	
	\mathbf{x}	the dra	iwings:				
		pages	1				, as originally filed
							, filed with the demand
		pages	NONE		_ , filed with	the letter of	
	X	the seq	luence listing part of the	he description:			as originally filed
		pages		1-21			, as originally filed , filed with the demand
		pages	NONE		Ciled with	the letter of	, The with the demand
		pages	NONE		, mea wim	the letter of	
		the lan	guage of publication	of the internat	tional applicati	on (under Rule 48.3)	h (under Rule 23.1(b)). b)). examination (under Rules 55.2 and/
3	. Wi	th regar	•	nd/or amino ac ried out on the	id sequence dis	closed in the internation	onal application, the international
		contair	ned in the internation	al application	in printed form	ı.	
	П	filed to	ogether with the inter	national applic	cation in comp	iter readable form.	
	H		ned subsequently to the				
	\Box		ned subsequently to the				
		The st	atement that the subse	quently furnish	ed written seque	ence listing does not g	go beyond the disclosure in the
		The sta				ble form is identical to	the writen sequence listing has
4	x	The a	mendments have resu	lted in the car	ncellation of:		
			the description, pages	NONE		_	
ı		32	the claims, Nos.				
i			the drawings, sheets			•	
,	5. F				amendments ha	d not been made, since	they have been considered to go
	<u> </u>	hever	ad the disclosure as filed	l as indicated in	the Supplement	al Box (Rule 70.2(c)).**	•
	in i	olacement this repo	t sheets which have been ort as "originally filed"	furnished to the and are not an	receiving Office nexed to this rep	in response to an invitation of since they do not	contain amendments (Rules 70.16
	**An	y replac	ement sheet containing	such amendmen	nts must be refer	red to under item 1 a	nd annexed to this report.



International application No.

PCT/US99/17167

citations and				
statement		O1 '	13, 14, 16-20	Y
Novelty (N)	Claims Claims	1-12, 15	N
		Clamis	112, 13	
Inventive	Step (IS)	Claims	13, 14, 16-20	Y
	• •	Claims	1-12, 15	N
			1-20	Y
Industrial	Applicability (IA)	Claims Claims	NONE	N
		Claims	NONE	
citations as	nd explanations (Rule	70.7)	s being anticipated by Ryseck et al. Ryseck et al te	
the polynucleoti 12) or pUC19	ng the polynucleotide encodition of the prior to Dot blot analysis plasmids.	(Claim 8). The	encoding V58 is shown in Fig. 1 (Claims 6, 9-11 (Claim 7) in which AMV reverse transcriptase was polynucleotides were transformed into M13-derived Article 33(2)-(4), because the prior art does not to	l vectors (Cla
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonical tibody.	set out in PCT aving polynucle st to the polype	(Claim 7) in which AMV reverse transcriptase was polynucleotides were transformed into M13-derived Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant problem, or a method of treatment. 100. Applicants made no direct argument against the bjections in national stage applications.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonical tibody.	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t
blot analysis usi the polynucleoti 12) or pUC19 Claims 13, 14, suggest a host polypeptide, an A response to stating only tha	ng the polynucleotide encoding the prior to Dot blot analysis plasmids. and 16-20 meet the criteria cell comprising the vector had tibody, agonist, or antagonist, written opinion was recent they elect to reserve the right	set out in PCT aving polynuclest to the polypereived 15 Nov 20 aght to address of	Article 33(2)-(4), because the prior art does not to tide encoding SEQ ID NO:1, the recombinant probable, or a method of treatment.	l vectors (Cla each or fairly oduction of t



International application No. PCT/US99/17167

Sun	plemental Box								
T	he used when	the snace	in any	of the	preceding	boxes	is not	sufficient))

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION	CLA	SZZ	IFI	CA'	TI	ON	í
----------------	-----	-----	-----	-----	----	----	---

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C07K14/00; C07H 17/00 C12P 14/00 and US CI.: 435/ 69.1. 252.3, 320.1, 325; 536/23.1; 530/350

PATENT COOPERATION TREAT

PCT

REC'D	2 5	JAN	2001
-------	-----	-----	------

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PF-0568 PCT	FOR FURTHER ACTION	Preliminary E	ation of Transmittal of International examination Report (Form PCT/IPEA/416)
International application No.	International filing date (day/s	month/year)	Priority date (day/month/year)
PCT/US99/17167	30 JULY 1999		31 JULY 1998
International Patent Classification (IPC) Please See Supplemental Sheet.	or national classification and I	PC	·
Applicant INCYTE PHARMACEUTICALS, INC	:. 		
This international preliming Examining Authority and is	ary examination report has	s been prepare	ed by this International Preliminary Article 36.
2. This REPORT consists of a	total of sheets.		
This report is also accom	manied by ANNEYES is she	heets containing	iption, claims and/or drawings which have rectifications made before this Authority ander the PCT).
These annexes consist of a to	otal of sheets.		
3. This report contains indication	ns relating to the following	items:	
I X Basis of the repo	•		
II Priority			
III Non-establishme	nt of report with regard to r	novelty, inventi	ive step or industrial applicability
IV Lack of unity of			
V X Reasoned stateme citations and expl	ent under Article 35(2) with reanations supporting such state	egard to novelty ement	, inventive step or industrial applicability:
VI Certain documents	scited		
VII Certain defects in	the international application		
VIII Certain observatio	ns on the international applica	ation	
Date of submission of the demand	D	ate of completio	n of this report
02 FEBRUARY 2000		06 DECEMBE	ER 2000
Name and mailing address of the IPE	A/US A	uthorized officer	MINOTOGA CENTER
Commissioner of Patents and Trad Box PCT Washington, D.C. 20231	emarks	KAREN COC	DELLA MAE COLLIN
Facsimile No. (703) 305-3230	Te	elephone No.	(703) 308-0196



International	application	No.

PCT/US99/17167

I.	Ba 	sis of th	ie report				
1. \	With	regard to	the elements of the inte	ernational application	n:*		
			rnational application				
			cription:	_ ,			
į		pages _					, as originally filed
		pages _					, filed with the demand
		pages _	NONE		, filed with the letter of	f	<u></u>
		r-6,, -					
ſ	x	the clai					
		pages _					, as originally filed
		pages _			, as amended (together		
		pages _	NONE	C1 1	ith the letter of		, med with the demand
		pages _	NUNE	, filed w	in the letter of		
Г	Ţ	the drav	wings:				
L	X	pages	٠,				, as originally filed
			NONE				, filed with the demand
					, filed with the letter of		
	X	the sequ	uence listing part of t	he description:			on originally filed
•		pages		1- 41			filed with the demand
			NONE		, filed with the letter of		men with the demand
		pages _	NONE		, mea with the letter of		
[the lang	guage of publication	of the internation	he purposes of internation and application (under Rupurposes of international presented in the purposes of international presented in the purpose of the purpose	ile 48.3(b)).	nder Rule 23.1(b)). nination (under Rules 55.2 and/
3.	Wit pre	th regard liminary	to any nucleotide ar examination was car	nd/or amino acid rried out on the b	sequence disclosed in the i	international : <u>;</u> :	application, the international
l		contain	ed in the internation	al application in	printed form.		
ı					tion in computer readable	form.	
ļ	믬		ed subsequently to the				
ļ	닏						
ļ	\sqsubseteq				computer readable form.	van met en bes	wand the disabeture in the
		internat	ional application as t	iled has been fun			
		The stat		ation recorded in o	computer readable form is ide	entical to the	writen sequence listing has
4.	X	The an	nendments have resu	ılted in the cance	ellation of:		
		X tl	he description, page	s NONE		-	
			he claims, Nos.	NONE			
			he drawings, sheets				
5.	_			""**	mendments had not been ma	ide, since they	have been considered to go
		bestone	d the disclosure as filed	d as indicated in the	he Supplemental Box (Rule 7	70.2(c)). **	
*	in t		the state of the same to a second	. E. wishad to the P	acaivina Offica in resnonse to a	an invitation u.	nder Article 14 are referred to ain amendments (Rules 70.16
*	unu ·*A*	v renlace	ment cheet containing	such amendments	s must be referred to under	item 1 and ar	nnexed to this report.



International application No.
PCT/US99/17167

stateme	ent			-
Nov	elty (N)	Claims	13, 14, 16-20	YES
NOV	city (14)	Claims	1-12, 15	NO
	0. (15)	Claims	13, 14, 16-20	YES
Inve	ntive Step (IS)		1-12, 15	
		Claims	1-20	YES
Indi	istrial Applicability (IA)	Claims	NONE	NO
the polym 12) or pU	sis using the polynucleotide encoducleotide prior to Dot blot analysis IC19 plasmids.	s (Claim 8). The p	encoding V58 is shown in Fig. 1 (Claims 6, 9) (Claim 7) in which AMV reverse transcriptase polynucleotides were transformed into M13-der	ived vectors (Claim
suggest a polypepti	host cell comprising the vector to de, antibody, agonist, or antagon	having polynucies hist to the polype	Article 33(2)-(4), because the prior art does notice encoding SEQ ID NO:1, the recombinant of the prior are does not the prior are does not treatment. 300. Applicants made no direct argument again objections in national stage applications.	•
suggest a polypepti A responstating or	host cell comprising the vector to de, antibody, agonist, or antagon	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
suggest a polypepti A responstating of	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
suggest a polypepti A responstating of	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
A respon	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
A respon	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
A respon	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
A respon	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•
A respon	host cell comprising the vector to de, antibody, agonist, or antagon se to this written opinion was recally that they elect to reserve the	naving polynucies hist to the polype ceived 15 Nov 20 right to address of	otide, or a method of treatment. On Applicants made no direct argument again	•



International application No. PCT/US99/17167

To be used when the space in any of the preceding boxes is not suffice Continuation of: Boxes I - VIII	Sheet 10
ontinuation of Doxes 1 - viii	•
LASSIFICATION:	
The International Patent Classification (IPC) and/or the National classific C(7): C07K14/00; C07H 17/00 C12P 14/00 and US C1.: 435/ 69.1. 252	ssification are as listed below: 3, 320.1, 325; 536/23.1; 530/350
C(7): C07K14700, C07H 17700 C121 14700 and C5 C1 1557 C5.11. 252	
	•